Previous Page  15 / 19 Next Page
Information
Show Menu
Previous Page 15 / 19 Next Page
Page Background

Gastro Education 2018

Journal of Clinical Gastroenterology and Hepatology

ISSN: 2575-7733

Page 33

September 06-07, 2018

London, UK

14

th

International Conference on

Gastro Education

I

nflammatory bowel diseases (IBD); Crohn’s disease and

ulcerative colitis (UC), are idiopathic, intestinal and systemic

inflammatory disorders which are immunologically mediated

with activation of plasma proteolytic cascades. Activation of

coagulation in IBD is related to activity and colonic extension of

the disease, but may be still persistent in quiescent stage. Factor

XIII seems to be as much coagulation factor as connective tissue

factor which may contribute to intestinal healing. Fibrinolytic

capacity is reduced in general circulation of IBDpatients, but a role

of recently recognized thrombin – activatable fibrinolytic inhibitor

is unclear. Platelets activation is a feature of IBD and contribute to

pathogenic inflammatory sequel. There are evidences that in turn

coagulation activation may mediate and amplify inflammatory

cascades in IBD especially via activating PARs related pathways.

The etiology of thromboembolism in IBD is likely multifactorial

but largely attributable to coagulation activation, and platelet

aggregation during systemic inflammation. Thromboembolic (TE)

complications in both Crohn’s disease and UC appear to have at

least 3-4 fold increased risk of developing compared to control

patients. Currently no single TE laboratory marker has predictive

value, but recently developed endogenous thrombin potential test

may predictive potential value in IBD. At present no interaction

between IBD and inherited factors of thrombophilia was found.

An efficacy of heparin treatment in UC is still controversial and

not established, although heparin is safe in UC flare. Prophylactic

anticoagulation against TE is currently defined, moderate and

high-risk patients should be considered for using moderate dose

of heparin.

Biography

Dr. Antoni worked in Thrombosis Research Center, Temple University Med-

ical School, Philadelphia, USA, having faculty position, investigated a role

of plasma and intestinal tissue kallikrein kinin system in experimental IBD,

in collaboration with Prof. Dr. RB Sartor, NC, and Chapel Hill, US. Currently

working as Professor, Silesian Medical University doing research, medical

practice, and teaching students. He has supervised two large research proj-

ects founded by Polish Ministry of Sciences related to pathogenesis and

treatment of human IBD. He also continued IBD coagulation study to eval-

uate link of coagulation-inflammation in joints and gut diseases, and anti

- platelets agents (Clopidogrel) interactions with proton pump inhibitors. My

recent projects were also related to the tissue kallikrein kinin system, and ki-

nin receptors in colorectal polyps, and colorectal cancer as well as a signifi-

cance of angiogenesis related to kinins and grow factors in ulcerative colitis.

astadnic@wp.pl

Involvement of coagulation and hemostasis in inflammatory

bowel diseases

Antoni Stadnicki

Medical University of Silesia, Poland

Antoni Stadnicki, J Clin Gastroenterol Hepatol 2018, Volume 2

DOI: 10.21767/2575-7733-C2-005